McKesson Corporation (MCK) has been demonstrating impressive trading performance, hitting a 52-week high, which greatly outpaces its competitors in the biotech market. This strong performance has been fuelled by robust revenue growth and a significant increase in earnings, even as some earnings estimates were missed. Full-year forecasts from analysts suggest a continued upswing for McKesson, with 10% revenue growth reported for Q2 of Fiscal 2024. MCK's strong performance seems to attract the attention of institutional investors who hold a whopping 88% stake in the company. Despite some days underperforming against competitors, the overall momentum remains strong. McKesson continues its demonstration of value as a stock, with a 340% gain for investors who bought it five years ago. However, the company's recent mixed earnings and increased share price have led to some suggesting a note of caution. Furthermore, the company's intrinsic value is reported to be potentially 82% above its share price, implying the stock may be undervalued. Finally, McKesson is preparing to sell its Canadian Rexall Pharmacy Group, signifying strategic business shifts.
Mckesson Corporation MCK News Analytics from Wed, 01 Nov 2023 07:00:00 GMT to Wed, 22 May 2024 20:47:00 GMT -
Rating 7
- Innovation 3
- Rumor -5
